Pfizer and Valneva Complete Recruitment for Phase 3 VALOR Trial for Lyme Disease Vaccine Candidate, VLA15 November 2023 11.28.2023 Corporate Medicines Arvinas and Pfizer Announce Updated Vepdegestrant (ARV-471) Data to be Presented at the 2023 San Antonio Breast Cancer Symposium ...
Three-dimensional culture of human breast cancer cells. Credit: NCI Center for Cancer Research, National Cancer Institute, National Institutes of Health. A new international clinical trial (PALOMA-3) has yielded positive data for the treatment of breast cancer using Pfizer’s Ibrance (palbociclib) i...
BREAST CANCER Mini Oral Presentation (Abstract 618MO) Saturday, September 14, 2:45 PM-4:15 PM CEST Phase 1b/2 first-in-class novel combination trial of next generation CDK4-selective inhibitor PF-07220060 and next generation CDK2-selective inhibitor PF-07104091 in HR+ HER2- metastatic b...
Supreme Court to reject a bid by the Wyeth unit of the pharmaceutical company Pfizer Inc. to obtain a full new trial on claims of an Arkansas woman that she developed breast cancer after taking a combination of hormone-therapy drugs.Wall Street Journal - Eastern EditionKENDALLBRENT...
The scoop:The selective estrogen receptor degrader (SERD) is for postmenopausal women or adult men with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer who've experienced disease progression following at least one line of endocrine therapy. In this field, fa...
(NYSE: PFE) today announced that updated clinical trial data for vepdegestrant (ARV-471) will be presented at the 2023 San Antonio Breast Cancer Symposium (SABCS). Vepdegestrant is a novel oral PROteolysis TArgeting Chimera (PROTAC®) estrogen receptor (ER) degrader currently ...
(NYSE: PFE) today announced that updated clinical trial data for vepdegestrant (ARV-471) will be presented at the 2023 San Antonio Breast Cancer Symposium (SABCS). Vepdegestrant is a novel oral PROteolysis TArgeting Chimera (PROTAC®) estrogen receptor (ER) degrader currently ...
“I’ve witnessed first-hand the positive impact of palbociclib in combination with endocrine therapy in patients with HR+, HER2– metastatic breast cancer.” Hope S. Rugo, MD, lead researcher and professor of medicine at the University of California San Francisco (UCSF) Helen...
Breast Cancer: As a single agent, for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) HER2-negative locally advanced or metastatic breast cancer. Select patients for therapy based on an FDA-approved companion diagnostic for TALZENNA. ...
Pfizer, the world's second largest drugmaker, said the drug preventedbreast cancerfrom worsening for 20.2 months in a trial involving 165 patients. Current medications do so for 10.2 months. The drug, known as palbociclib, is among a new class ofcancer drugsthat target specific proteins to blo...